Saturday, Sep 23rd

Last update04:24:00 PM

Error
  • JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING
  • JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING
  • JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING
  • JLIB_APPLICATION_ERROR_COMPONENT_NOT_LOADING
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_contact, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_content, 1
  • Error loading component: com_users, 1

Allergic bronchopulmonary aspergillosis (ABPA) remains an important entity to clinicians because of the fact that the condition is glucocorticoid sensitive, and early diagnosis and treatment can prevent progression to end-stage lung disease. The disease has a global presence albeit with differences in clinical presentation in developed versus the developing countries. In the developing countries, the condition is often misdiagnosed as pulmonary tuberculosis and most patients present with bronchiectasis. Despite six decades of research, there is still no consensus regarding its epidemiology, pathogenesis, categorization, diagnosis, and treatment. We proposed a consortium approach to work together and exchange ideas for resolving the problems in ABPA complicating asthma. These questions led the International Society for Human and Animal Mycology (ISHAM) to approve a working group on allergic bronchopulmonary aspergillosis complicating asthma in September 2011.This working group comprises clinicians, scientists and mycologists involved in all aspects of ABPA, including clinical surveillance, epidemiology, genetic susceptibility factors, diagnosis, and treatment, develop a consortium to work together and to exchange ideas for resolving the problems. As International Society for Human and Animal Mycology (ISHAM) has undertaken a special effort in establishment of Working Groups on particular themes and topics, we have planned to develop this network under the umbrella of ISHAM, though participation in the consortium is open to everybody with interest in ABPA. However, as ISHAM is such dynamic organization with strong commitment in the field of Medical Mycology, we would encourage everyone to join ISHAM (www.isham.org) if you are not a member already although this is not a prerequisite to join the ABPA working group.

Allergic bronchopulmonary aspergillosis (ABPA) remains an important entity to clinicians because of the fact that the condition is glucocorticoid-sensitive, and early diagnosis and treatment can prevent progression to end-stage lung disease. The disease has a global presence albeit with differences in clinical presentation in developed versus the developing countries. In the developing countries, the condition is often misdiagnosed as pulmonary tuberculosis and most patients present with bronchiectasis. Despite six decades of research, there is still no consensus regarding its epidemiology, pathogenesis, categorization, diagnosis, and treatment. We proposed to develop a consortium to work together and exchange ideas for resolving the problems. These questions led the International Society for Human and Animal Mycology to approve a working group on allergic bronchopulmonary aspergillosis complicating asthmatics in September 2011.This working group comprises clinicians, scientists and mycologists involved in all aspects of ABPA, including clinical surveillance, epidemiology, genetic susceptibility factors, diagnosis, and treatment, develop a consortium to work together and to exchange ideas for resolving the problems. As International Society for Human and Animal Mycology (ISHAM) has undertaken a special effort in establishment of Working Groups on particular themes, we have planned to develop this network under the umbrella of ISHAM, though participation in the consortium is open to everybody with interest in ABPA. However, as ISHAM is such dynamic organization with strong commitment in the field of Medical Mycology, we would encourage everyone to join ISHAM if you are not a member already although this is not a condition to join the ABPA working group. You can visit the ISHAM website at www.isham.org to learn about its activities.

You are here: Home Sample Category Welcome